Triplet Could Become a New Standard in Tough-to-Treat CLL

Published Date: 06 Jul 2026

Adding a non-covalent BTK inhibitor improved progression-free survival

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma

2.

Triplet Could Become a New Standard in Tough-to-Treat CLL

3.

Dasatinib Fails to Improve Outcomes in CBF-AML

4.

Financial hardship common in patients with cancer

5.

New study links air pollution with higher rates of head and neck cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot